Covid-19 roundup: Russian biotech seeks permission to produce remdesivir generic; Why did BARDA fund plasma company part-owned by Rick Santorum?
Man with flu-COVID infection found in the US – but he's not the first
Regeneron, Lilly Setbacks Raise Questions on the Effectiveness of Antibodies in Severe COVID-19
J&J Strikes Covid-19 Vaccine Manufacturing Deal With Aspen
BDX Inks Deal With Dutch Gov. For 9M Covid-19 Antigen Tests
AstraZeneca Sells Rights To Hypertension Drugs For $400M
Regeneron Halts Covid-19 Trial For High-Flow Oxygen Patients; Shares Fall
Eli Lilly Nabs $312.5M US Army Contract For Covid-19 Treatment
Astrazeneca Scores $286.9M US Army Contract For Covid Vaccine
Opko Health Tanks 10% Despite Solid Q3 Covid Testing Revenue
Amount of COVID viral RNA detected at hospital admission predicts how patients will fare
Healthcare And Biotech Outlook –Final Quarter of 2020
Moderna Scores $1.1B From Covid-19 Vaccine Deposits; Shares Rise 3%
Remdesivir for COVID-19: FDA approved but still unproven
Novartis Snaps Up Vedero Bio In $280M Deal; Street Says Buy
Eli Lilly Strikes $375M Covid-19 Antibody Supply Deal With US Government
Gilead Q3 revenue rise bolstered by $873m Veklury sales
Covid-19 roundup: Boehringer pulls a drug out of the pipeline for a PhII Covid-19 trial; Novavax delays PhIII trial in US, with PhII data coming Friday
Sanofi, Merck Join Forces On Ketruda, THOR-707 Combo In Cancer
Gilead Cuts 2020 Guidance As Remdesivir Sales Disappoint
Gilead cuts 2020 sales outlook as Covid-19 drug remdesivir falls short
US buys Lilly COVID antibody, as effectiveness questions remain
Covid-19 roundup: Boehringer pulls a drug out of the pipeline for a PhII Covid-19 trial; Novavax delays PhIII trial in US, with PhII data coming Friday;
Covid-19 roundup: Novavax delays PhIII trial in US, with PhII data coming Friday; CBER director promises 'safe and effective' vaccine in op-ed
US Hospitalizations Soar Almost 40% In One Week; Wisconsin Sees New COVID-19 Record: Live Updates
Russia’s COVID-19 vaccine filed with WHO, as MHRA reviews Moderna shot
BioSig abandons COVID-19 drug trial on safety concerns
France Weighs Return To Lockdown As Russia Refuses Despite Spike In COVID-19 Cases, Deaths: Live Updates
Good Entry Point for Gilead Sciences (GILD)? Not Just Yet, Says Analyst
Weekly Market Outlook: BOC, BOJ, ECB and corporate earnings in focus